IMI announces a new total of 23 unique projects to boost drug innovation

The Innovative Medicines Initiative (IMI), currently the largest public-private partnership in the biopharmaceutical sector, launches its second wave of research projects which address key areas including cancer, immune-mediated diseases, infectious disorders and electronic health. With 23 projects now up and running, over €450 million is now committed by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) on a uniquely large scale. IMI is shaping the current and future research and development of innovative drugs in Europe.

Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science said: "By speeding up drug development across Europe, the investments made by the IMI will ultimately save and improve lives, as well as making a major contribution to the Innovation Union and to growth and jobs."

With a budget of €172 million, 8 new IMI projects are being launched over the coming weeks. The project consortia include 21 EFPIA members represented by 65 EFPIA teams who are working together with partners from 103 academic teams, 23 SMEs and 2 patient organisations.

Roch Doliveux, CEO of UCB and member of the Board of the European Federation of Pharmaceutical Association (EFPIA) says, "The industry has reached an inflection point where public private partnerships, based on open innovation networks, will improve the efficiency of the pharmaceutical companies in bringing safe, efficacious, cost-effective treatments to patients. EFPIA considers IMI as a key instrument to implement the new business models which will ensure the sustainability of pharmaceutical industries across Europe."

The 8 new projects deal with health concerns, identified by scientific priority and industry needs, will develop new patient treatments for cancer, rheumatoid arthritis and infectious diseases.

PREDECT, ONCOTRACK, QUIC-CONCEPT all focus on developing better tools for diagnosing and treating lung, prostate, ovarian, breast and colon cancers and are covered by IMI's 'efficacy' pillar along with RAPP-ID and BTCure which aim to facilitate the development of novel diagnostic tools related to infectious diseases and rheumatoid arthritis. DDMoRe, OPEN-PHACTS and EHR4CR fall under IMI's 'Knowledge Management' pillar in developing new methods dedicated to common standards and sharing data on common platforms for more efficient drug-development and patient treatments for the future. The projects will run for between 36 - 60 months. Detailed factsheets are available on the IMI website: www.imi.europa.eu

Ruxandra Draghia-Akli, Director Health in the Research & Innovation DG of the European Commission says, "It is encouraging that IMI is launching 8 new innovative projects in areas as different as cancer or diagnostic tools for infectious diseases. Results from IMI projects that have been selected from the first call already demonstrate how this novel public-private collaboration is delivering results that can make a difference in how drugs are developed, for the benefit of patients in Europe and worldwide."

The first-wave IMI projects, now up and running for around one year, are already providing tangible benefits, delivered through the constructive engagement of industry competitors, academia, patient groups and SMEs. These first contributions are made possible by the collaborative spirit of scientists from industry and academia along with SMEs, patient organisations and regulatory agencies who form the IMI project consortia.

Michel Goldman, Executive Director of IMI says, "The uniqueness of what IMI is doing to facilitate innovation in the biopharmaceutical sector is the scale of the collaborative research now being undertaken and it’s changing how drug development happens. It is clear that IMI is performing a vital role in working towards finding better solutions for patients across Europe."

IMI is fostering a new environment of collaboration and innovation to shape the future of the biopharmaceutical sector in Europe.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...